Press & Media

PlexBio Presents Multiplex Mutation Analysis for Cancer Management by πCode Technology at Molecular Med Tri-Con 2018


San Francisco, CA (February 14, 2018) – PlexBio Co., Ltd. presented scientific data on the development and use of a series of novel multiplex assays on the company’s IntelliplexTM instrument system at this week’s 25th Molecular Med Tri-Conference in San Francisco, CA. ...more

PlexBio Expands Collaboration with Denka to Co-Develop an Infectious Disease Diagnostic System


Taipei, Taiwan – January 25, 2018 – PlexBio Co., Ltd. announced today that it plans to expand its collaboration agreement with Denka Co., Ltd. to include a new program to co-develop a molecular diagnostic system for Infectious Disease ...more

PlexBio Ranks Among Top Growing Companies in Asia Pacific


Taipei, Taiwan – January 5, 2018 - PlexBio Co., Ltd. has been recognized as being among the fastest growing technology companies in the Asia Pacific region according to the Deloitte Technology Fast 500TM awards program for 2017. ...more

PlexBio Receives CE Mark for its IntelliPlex™ Instrument System


PlexBio Co., Ltd. has received clearance to apply the CE Mark to its IntelliPlex™ 1000 πCode Processor and its PlexBio™ 100 Fluorescent Analyzer as IVD instruments. ...more

PlexBio Receives CE Mark for PlexBio™ 100 Fluorescent Analyzer


Taipei, Taiwan – August 28, 2017 - PlexBio Co., Ltd, an emerging multi-national diagnostic company, has received CE mark for its IVD instrument, the PlexBio™ 100 Fluorescent Analyzer, and achieves an important milestone for the Company’s market strategy in Europe. ...more

< 1 |2 | 3 | 4 | >